Table 1.
Ridaforolimus-Eluting Stent (N=958, 1276 Lesions) | Zotarolimus-Eluting Stent (N=961, 1277 Lesions) | |
---|---|---|
Age, y | 63.7±10.2 | 63.1±10.3 |
Male sex | 78.3 (750/958) | 81.9 (787/961) |
Diabetes mellitus | 32.8 (314/958) | 32.3 (310/961) |
Hypertension | 72.4 (687/949) | 74.0 (704/951) |
Hyperlipidemia | 80.4 (759/944) | 78.1 (744/953) |
Previous myocardial infarction | 31.1 (298/958) | 30.5 (293/961) |
Previous PCI | 38.8 (372/958) | 38.2 (367/961) |
Previous coronary bypass surgery | 8.8 (84/958) | 9.6 (92/961) |
Current smoker | 23.4 (224/958) | 19.4 (186/961) |
LV ejection fraction | 55.5±9.8 | 55.8±9.3 |
Clinical presentation | ||
Stable coronary disease | 59.3 (568/958) | 61.3 (589/961) |
ACS | 40.7 (390/958) | 38.7 (372/961) |
Elevated cardiac biomarkers* | 27.0 (206/763) | 28.2 (216/766) |
Target lesion vessel | ||
Left main | 1.1 (14/1276) | 0.4 (5/1277) |
Left anterior descending | 40.7 (519/1276) | 39.7 (507/1277) |
Right coronary | 32.0 (408/1276) | 32.2 (411/1277) |
Left circumflex | 24.4 (311/1276) | 25.1 (320/1277) |
Bypass graft | 1.9 (24/1276) | 2.7 (34/1277) |
Multivessel disease | 29.4 (282/958) | 29.3 (282/961) |
Angiographic complexity | ||
No. lesions treated per patient | 1.3±0.6 | 1.3±0.6 |
Reference vessel diameter (mm) | 2.73±0.49 | 2.74±0.49 |
Lesion length (mm) | 17.7±10.8 | 17.9±10.7 |
SYNTAX score | 11.2±7.4 | 11.0±7.2 |
TIMI 0 flow in target vessel | 9.7 (92/953) | 7.7 (74/957) |
Bifurcation lesion | 28.6 (365/1276) | 29.1 (371/1277) |
Ostial lesion | 6.0 (77/1276) | 6.1 (78/1277) |
Chronic total occlusion | 7.2 (92/1272) | 5.8 (74/1276) |
Overlapping stents | 24.7 (237/958) | 23.1 (222/961) |
Use of atherectomy device | 0.9 (9/958) | 1.1 (11/961) |
Thrombus present | 3.4 (43/1270) | 3.0 (38/1275) |
Severe calcification | 13.3 (169/1272) | 10.5 (134/1274) |
Severe tortuosity | 3.9 (50/1271) | 2.8 (35/1272) |
ACC lesion class B2/C | 57.5 (733/1275) | 58.9 (752/1277) |
ACC indicates American College of Cardiology; ACS, acute coronary syndrome; LV, left ventricle; PCI, percutaneous coronary intervention; SYNTAX, synergy between percutaneous coronary intervention with taxus and cardiac surgery; and TIMI, thrombolysis in myocardial infarction. Values are % (n/N) or mean±SD.
Troponin I or T ≥3X upper limit of normal.